The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 18, 2019

Filed:

Dec. 16, 2015
Applicant:

Macau University of Science and Technology, Taipa Macau, CN;

Inventors:

Kam Wai Wong, Taipa, CN;

Yuen Kwan Law, Taipa, CN;

Thomas Efferth, Mainz, DE;

Su-Wei Xu, Taipa, CN;

Sami Hamdoun, Taipa, CN;

Liang Liu, Taipa, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/19 (2006.01); A61K 31/337 (2006.01); A61K 31/553 (2006.01); A61K 31/704 (2006.01); A61K 31/7048 (2006.01); A61K 33/24 (2019.01);
U.S. Cl.
CPC ...
A61K 31/19 (2013.01); A61K 31/337 (2013.01); A61K 31/553 (2013.01); A61K 31/704 (2013.01); A61K 31/7048 (2013.01); A61K 33/24 (2013.01);
Abstract

A quinonemethide triterpenoid is administered to subjects with multidrug-resistant cancer, in particular a cancer with enhanced expression and/or functional activity of ABC transporter proteins such as P-glycoprotein and/or an apoptosis-deficient, in particular p53-, Bax- or Bak-deficient, cancer, i.e. specific subgroups of subjects with cancer. The quinonemethide triterpenoid is suitable to treat cancer allowing for an accumulation of cytotoxic or therapeutic compounds in the cells while having exceptionally increased cytotoxic activity towards the multidrug-resistant cancer cells and while allowing for an increased activity of chemotherapeutic compounds. Methods for specifically targeting cancer cells with multidrug-resistance and methods for potentiating the activity of a chemotherapeutic compound in those cancer cells are also disclosed. A kit including a quinonemethide triterpenoid and a chemotherapeutic compound is also provided.


Find Patent Forward Citations

Loading…